Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bright Minds BiosciencesDRUG -2.36%34 EV-to-EBITDA is -23.02 as of Jul. 23, 2026. GuruFocus rates DRUG with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 400 Biotechnology companies, Bright Minds Biosciences ranks worse than 249999.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bright Minds Biosciences's enterprise value is $520.75 Mil.
Bright Minds Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-22.63 Mil. Therefore, Bright Minds Biosciences's EV-to-EBITDA for today is -23.02.
The historical rank and industry rank for Bright Minds Biosciences's EV-to-EBITDA or its related term are showing as below:
DRUG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -23.55 Med: 0 Max: 0
Current: -23.55
DRUG's EV-to-EBITDA is ranked worse than 100% of 400
companies
in the Biotechnology industry
Industry Median: 12.15
vs DRUG: -23.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bright Minds Biosciences's PE Ratio (TTM) for today is calculated as:
Bright Minds Biosciences's share price for today is $75.31.
Bright Minds Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.457.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bright Minds Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bright Minds Biosciences EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bright Minds Biosciences's EV-to-EBITDA falls into.
Bright Minds Biosciences's current Enterprise Value is $520.75 Mil.
Bright Minds Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bright Minds Biosciences (DRUG) has a EV-to-EBITDA of -23.02 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bright Minds Biosciences. According to the industry distribution chart, Bright Minds Biosciences ranks #999999 out of 400 companies in the Biotechnology industry.
Is Bright Minds Biosciences' EV-to-EBITDA too high?
Bright Minds Biosciences' current EV-to-EBITDA is -23.02. Based on the distribution chart, Bright Minds Biosciences ranks #999999 out of 400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bright Minds Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Bright Minds Biosciences' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bright Minds Biosciences ranks #999999 out of 400 companies for EV-to-EBITDA. This places Bright Minds Biosciences in the lower half of its industry. The industry median EV-to-EBITDA is 12.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.15, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bright Minds Biosciences. For the Biotechnology industry, the median EV-to-EBITDA is 12.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bright Minds Biosciences's current EV-to-EBITDA is -23.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bright Minds Biosciences stock overvalued right now?
Bright Minds Biosciences (DRUG) has a current EV-to-EBITDA of -23.02. The current EV-to-EBITDA is -23.02. Bright Minds Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bright Minds Biosciences (DRUG), the current EV-to-EBITDA is -23.02 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
34GF Score
Get the complete analysis for DRUG
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRUG has been successfully added to your 
